David A. Siegel Uni Qure N.V. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uni Qure N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 214,700 shares of QURE stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
214,700
Previous 289,500
25.84%
Holding current value
$1.06 Million
Previous $1.51 Million
36.15%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding QURE
# of Institutions
141Shares Held
33.7MCall Options Held
1.54MPut Options Held
389K-
Vestal Point Capital, LP New York, NY4.75MShares$23.4 Million1.59% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.65MShares$13.1 Million0.79% of portfolio
-
Black Rock Inc. New York, NY1.93MShares$9.49 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.9MShares$9.37 Million0.78% of portfolio
-
Schroder Investment Management Group London, X01.74MShares$8.58 Million0.01% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $230M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...